Competitive Rivalry

TPST competes in early-stage oncology where many peers pursue similar immuno-oncology assets, keeping differentiation limited and pricing power effectively absent.

Because commercialization is not yet established, rivalry is expressed through capital-market competition for investor attention rather than product pricing, unlike approved-drug peers.

Global biopharma incumbents and better-capitalized clinical-stage peers can outspend TPST on trials and partnering, intensifying structural pressure on margins.

Threat Of New Entrants

Scientific entry barriers are meaningful in oncology, but platform access and outsourced development lower hurdles versus large-cap peers with proprietary manufacturing and distribution.

TPST lacks the scale advantages that protect commercial-stage biopharma, so new entrants can still emerge around adjacent mechanisms and compete for the same capital.

Patent and regulatory requirements slow entry, yet they do not create durable pricing insulation for TPST because peer pipelines can still substitute at the clinical stage.

Bargaining Power Of Suppliers

TPST relies on CROs, CMOs, and specialized clinical vendors, but these inputs are broadly available, limiting supplier leverage versus peers with similar outsourced models.

For a small biotech, limited internal scale reduces negotiating power on trial services and manufacturing, which can pressure cash burn more than at larger peers.

Supplier concentration in niche assay and biologics capabilities can raise costs episodically, but the effect is structural rather than dominant across the industry.

Bargaining Power Of Buyers

TPST has no meaningful commercial buyers yet, so end-market pricing power is not realized and remains far weaker than approved oncology peers.

Future buyers will be concentrated payers and providers, which typically exert strong reimbursement pressure on novel oncology drugs and compress margins industry-wide.

Compared with marketed-drug peers, TPST’s lack of approved products leaves it with minimal ability to influence price, formulary access, or adoption terms.

Threat Of Substitutes

In oncology, established standards of care, combination regimens, and competing mechanisms create high substitution risk, especially for unproven assets like TPST’s.

Because many peers target overlapping tumor types and pathways, clinical substitution can occur before commercialization, limiting TPST’s relative strategic flexibility.

Alternative treatment modalities and faster-moving competitors can displace a TPST asset if efficacy or safety is not clearly superior, weakening long-run pricing power.

Overall Score

TPST operates in a structurally tough early-stage oncology segment where rivalry, substitutes, and buyer power materially limit future pricing power versus global peers.